Table 1.

Demographic and CSF characteristics of cases^a

Case no.	Age (yr)	Sex	Symptoms	Symptom onset dayb	Voriconazole initiation dayb	Day CSF collectedb	CSF WBC (cells/mm3)	CSF differentiation	CSF RBC (cells/mm3)	CSF protein (mg/dl)	CSF glucose (mg/dl)	CSF fungal culture	CSF fungal PCR (CDC)	CSF (1,3)-β-d-glucan (pg/ml)
1d
a	55	F	HA, ISP, blurred vision	∼7	45	57	1,224	69% PMN, 13% lymph, 18% mono	2,793	164	55	Neg	Negc	2,396
b	55	F	HA, ISP, blurred vision	∼7	45	73	72	43% PMN, 6% lymph, 51% mono	0	53	46	Neg	Negc	701
2	37	M	HA, ISP	∼4	13	28	5	50% lymph, 50% mono	0	48	74	Neg	Neg	<31
3	66	F	ISP→HA	19	38	72	2	87% lymph, 13% mono	3	37	54	Neg	Negc	96
4	45	F	URI→HA, neck stiffness	∼42	NA	∼42	1	100% lymph	0	26	67	Neg	NA	<31
5	66	M	None	NA	50	50	0	NA	2	49	52	Neg	NA	39

^aF, female; M, male; HA, headache; ISP, injection site pain; URI, upper respiratory illness symptoms (rhinorrhea, cough, pharyngitis); PMN, polymorphonuclear cells (neutrophils); lymph, lymphocytes; mono, monocytes; Neg, negative; NA, not available.

^bDays after epidural steroid injection date.

^cSent from prior CSF sample.

^dSame patient; two CSF samples.